Real-world data for direct stage-specific costs of melanoma healthcare.

Real-world data for direct stage-specific costs of melanoma healthcare.
Br J Dermatol. 2020 Jan 29;:
Authors: Buja A, Rivera M, De Polo A, Zorzi M, Carpin E, Vecchiato A, Del Fiore P, Martin G, Saia M, Baldo V, Rugge M, Rossi CR
Abstract
In Europe, melanoma is the fourth most common cancer diagnosed in young adults (20 to 45 years old) [1]. It also has one of the fastest-growing incidence rates globally, and this trend is expected to continue in all European countries [2]. Thus, also due to the costly new treatment options available, the economic burden of this illness is expected to keep increasing as well [3].
PMID: 31997306 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - January 28, 2020 Category: Dermatology Authors: Buja A, Rivera M, De Polo A, Zorzi M, Carpin E, Vecchiato A, Del Fiore P, Martin G, Saia M, Baldo V, Rugge M, Rossi CR Tags: Br J Dermatol Source Type: research